Fulgent genetics, inc. (FLGT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flow from operating activities:
Net loss

-1,956

-296

1,462

331

-1,908

-2,053

-595

-1,049

-1,910

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

232

813

-1,107

-4,510

-543

Income (loss) from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-18

59

Income (loss) from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

813

-1,107

-4,492

-602

Adjustments to reconcile net loss to net cash provided by operating activities:
Equity-based compensation

924

938

951

737

583

598

588

573

545

581

549

424

565

535

2,494

0

1,625

Depreciation

569

558

503

511

535

538

547

562

516

-

-

-

-

-

-

-

-

Noncash lease expense

108

107

105

101

100

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

412

420

303

248

199

Loss on disposal of fixed asset

-

-

-

-

-

0

-33

-4

-51

-

-

-

-

-

-

-

-

Amortization of premium of marketable securities

105

54

8

7

37

58

79

78

82

84

90

101

95

-

-

-

-

Provision for bad debt

121

-

-

-

-

79

0

182

48

-

-

-

-

-

-

-

-

Deferred taxes

-

-

-

-

-

923

-352

-101

-434

-

-

-

-

-

-

-

-

Equity loss in investee

-249

-174

-175

-149

-279

-234

-210

-246

-245

-247

-172

-105

0

-

-

-

-

Other

42

-11

-3

-66

28

-26

20

-10

-28

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-104

1,427

-220

1,046

-1,414

-23

1,003

277

713

545

-581

-415

237

61

1,612

-27

676

Other current and long-term assets

924

76

-267

-119

-64

124

-193

-147

125

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-9

721

482

343

-19

198

121

81

Accounts payable

1,907

-238

33

-203

79

277

1,169

-1,562

218

-377

569

-314

-241

-484

1,010

189

379

Taxes payable

-

-

-

-

-

-

-

-

-

0

-1

-229

106

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-954

1,130

158

115

-95

159

919

-107

-508

195

48

Income tax payable

34

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities and other current liabilities

268

-

-

-

-7

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-101

-99

-122

-95

-93

-

-

-

-

-

-

-

-

-

-

-

-

Cash provided by continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

1,254

798

1,492

892

Cash used in discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-14

-17

Net cash provided by operating activities

1,366

-116

3,903

675

1,055

778

-105

-57

-1,291

-1,241

500

564

1,508

1,254

798

1,478

875

Cash flow from investing activities:
Purchases of fixed assets

796

461

88

499

134

123

1,047

36

1,116

1,141

237

1,427

90

409

2,816

386

177

Purchase of marketable securities

7,992

40,231

1,668

4,190

5,988

11,022

1,695

6,787

4,683

6,407

1,670

802

2,780

-

-

-

-

Maturities of marketable securities

4,926

4,750

8,100

7,900

3,600

8,609

7,704

5,806

5,850

5,785

1,800

2,600

1,000

-

-

-

-

Net cash used in investing activities

-3,862

-36,079

6,344

3,211

-2,522

-2,536

4,962

-1,527

51

-1,763

-2,568

4,152

-1,870

-39,416

-2,816

-386

-177

Cash flow from financing activities:
Proceeds from exercise of stock options

12

12

17

5

4

5

1

7

2

-

-

-

-

-

-

-

-

Proceeds from public offerings of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of public offering costs

130

-

-

-

-

-

-

-

-

0

0

0

801

-

-

-

-

Repurchases of capital stock

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-164

27,639

1,127

5

4

5

1

7

2

4

4

23

-801

37,854

-5,837

13,772

0

Effect of exchange rate changes on cash and cash equivalents

-3

-

-

-

15

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-2,663

-

-

-

-1,448

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-43

22

-

-

-

-

-

-

-

-

Net decrease in cash

-

-

-

-

-

-

-

-1,620

-1,216

-

-

-

-

-

-

-

-

Net decrease in cash

-

-

-

-

-

-

-

-

-

-

-

-

-1,163

-308

-7,855

14,864

698

Supplemental disclosures of non-cash investing and financing activities:
Fixed assets included in accounts payable

43

-

-

-40

45

-

-

1,005

6

115

-44

932

11

1,076

-2,312

2,250

159

Purchase of marketable securities in other current liabilities

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offerings costs included in accounts payable

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial public offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

243